2023 was a tough year for the biopharma industry, with quite a few corporations downsizing and restructuring their workforces to stay afloat. You'll find indications of recovery, as mergers and acquisitions picked up over the pharmaceutical and lifestyle sciences marketplace within the latter Component of 2023 and have continued their https://sites.google.com/view/bio-sites/blog